Clinical trial of danazol for benign breast disease
Non-randomised trial
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
A clinical trial found danazol provided relief of symptoms and nodularity in patients with fibrocystic breast disease, with mild side effects and symptom recurrence after discontinuation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A clinical trial of danazol was undertaken in 30 patients with severe fibrocystic disease of the breasts. Twenty-three of the patients continued the drug for five or six months to allow adequate evaluation. Partial or complete relief of breast pain, tenderness, and nodularity occurred in all patients studied. One previously unsuspected carcinoma of the breast was discovered after three months of therapy. Side effects from the drug were generally mild. Recurrence of symptoms and physical findings occurred in most patients after the drug was discontinued but have not been as severe as prior to therapy.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (5)
- Danazol alters mitochondria metabolism of fibrocystic breast Mcf10A cells 2017
- Evaluation and management of breast pain 2004
- The treatment of symptomatic benign breast disease with danazol 1988
- Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease 1982
- Fibrocytic breast disease: current status of diagnosis and treatment 1982
Source provenance
- openalex
- last seen: 2026-05-10T11:27:50.310468+00:00
- pubmed
- last seen: 2026-10-08T21:45:11.424976+00:00
License: CC0
· commercial use OK